尼妥珠单抗治疗食管鳞状细胞癌的应用进展

摘要/Abstract

摘要：

食管鳞状细胞癌（ESCC）是我国食管癌最主要的病理类型,近年来随着分子靶向药物的发展,靶向治疗开始成为ESCC治疗领域的研究热点。尼妥珠单抗是我国第一个以表皮生长因子受体（EGFR）为靶点的人源化单克隆抗体,已被批准用于早期或局部晚期鼻咽癌的治疗。多项Ⅱ~Ⅲ期临床试验对尼妥珠单抗在ESCC治疗中的应用进行了探索,证实其在治疗中晚期ESCC中具有显著的疗效与生存获益,同时具备良好的安全性。

关键词:食管肿瘤,尼妥珠单抗,靶向治疗

Abstract:

Esophageal squamous cell carcinoma （ESCC） is the most predominant pathological type of esophageal cancer in China. In recent years, with the development of molecular targeted drugs, targeted therapy has become a hot research topic in the field of ESCC treatment. Nimotuzumab is the first humanized monoclonal antibody targeting epidermal growth factor receptor （EGFR） in China, which has been approved for the treatment of early or locally advanced nasopharyngeal carcinoma. Several phase Ⅱ-Ⅲ clinical trials have explored the use of nimotuzumab in the treatment of ESCC, confirming its significant efficacy and survival benefit in the treatment of advanced ESCC, as well as its favorable safety profile.

Key words:Esophageal neoplasm,Nimotuzumab,Targeted therapy

戴李宸, 胡莉钧, 于静萍. 尼妥珠单抗治疗食管鳞状细胞癌的应用进展[J]. 国际肿瘤学杂志, 2022, 49(8): 484-489.

Dai Lichen, Hu Lijun, Yu Jingping. Advances of nimotuzumab in the treatment of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(8): 484-489.

参考文献40

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660. doi:10.3322/caac.21660
[2]	Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma[J]. Gastroenterology, 2018, 154(2): 360-373. DOI: 10.1053/j.gastro.2017.08.023. doi:10.1053/j.gastro.2017.08.023
[3]	Yang J, Liu X, Cao S, et al. Understanding esophageal cancer: the challenges and opportunities for the next decade[J]. Front Oncol, 2020, 10: 1727. DOI: 10.3389/fonc.2020.01727. doi:10.3389/fonc.2020.01727
[4]	Mateo C, Moreno E, Amour K, et al. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity[J]. Immunotechnology, 1997, 3(1): 71-81. DOI: 10.1016/S1380-2933(97)00065-1. doi:10.1016/S1380-2933(97)00065-1pmid:9154469
[5]	Yang YM, Hong P, Xu WW, et al. Advances in targeted therapy for esophageal cancer[J]. Signal Transduct Target Ther, 2020, 5(1): 229. DOI: 10.1038/s41392-020-00323-3. doi:10.1038/s41392-020-00323-3
[6]	Zhao L, He LR, Xi M, et al. Nimotuzumab promotes radiosensiti-vity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3[J]. J Transl Med, 2012, 10: 249. DOI: 10.1186/1479-5876-10-249. doi:10.1186/1479-5876-10-249pmid:23232108
[7]	Yu Y, Guan H, Jiang L, et al. Nimotuzumab, an EGFR‑targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma[J]. Int J Oncol, 2020, 56(4): 945-956. DOI: 10.3892/ijo.2020.4981. doi:10.3892/ijo.2020.4981
[8]	王军, 王雯, 郭银, 等. 尼妥珠单抗对食管鳞癌ECA-109和TE-13细胞放射敏感性的影响及其发生机制[J]. 中华肿瘤杂志, 2016, 38(10): 732-738. DOI: 10.3760/cma.j.issn.0253-3766.2016.10.004. doi:10.3760/cma.j.issn.0253-3766.2016.10.004
[9]	Rawat S, Tandan H, Patel S, et al. Safety and efficacy of nimotuzumab with concurrent chemoradiotherapy in unresectable locally advanced squamous cell carcinoma of head and neck: an Indian rural hospital experience[J]. South Asian J Cancer, 2019, 8(1): 52-56. DOI: 10.4103/sajc.sajc_76_18. doi:10.4103/sajc.sajc_76_18
[10]	Qu L, Wang JH, Du JX, et al. Use of nimotuzumab combined with cisplatin in treatment of nasopharyngeal carcinoma and its effect on expressions of VEGF and MMP-2[J]. Clin Transl Oncol, 2021, 23(7): 1342-1349. DOI: 10.1007/s12094-020-02522-4. doi:10.1007/s12094-020-02522-4pmid:33517541
[11]	Diaz Miqueli A, Blanco R, Garcia B, et al. Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibo-dies with different affinities[J]. Hybridoma (Larchmt), 2007, 26(6): 423-431. DOI: 10.1089/hyb.2007.0516. doi:10.1089/hyb.2007.0516
[12]	孙文泽, 苏进, 施璠, 等. EGFR与VEGF在食管鳞癌组织中的表达及其与疗效的关系[J]. 现代肿瘤医学, 2019, 27(6): 981-985. DOI: 10.3969/j.issn.1672-4992.2019.06.018. doi:10.3969/j.issn.1672-4992.2019.06.018
[13]	Hatogai K, Fujii S, Kojima T, et al. Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma[J]. J Cancer Res Clin Oncol, 2017, 143(11): 2351-2361. DOI: 10.1007/s00432-017-2482-7. doi:10.1007/s00432-017-2482-7pmid:28756492
[14]	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075. DOI: 10.1016/S0140-6736(17)33326-3. doi:S0140-6736(17)33326-3pmid:29395269
[15]	Chen XX, Zhong Q, Liu Y, et al. Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing[J]. Nat Commun, 2017, 8(1): 524. DOI: 10.1038/s41467-017-00650-0. doi:10.1038/s41467-017-00650-0
[16]	Shapiro J, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9): 1090-1098. DOI: 10.1016/S1470-2045(15)00040-6. doi:S1470-2045(15)00040-6pmid:26254683
[17]	Lerut T. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus: the (NEOCRTEC5010) trial-a timely and welcome clinical trial from the Far East[J]. J Thorac Dis, 2018, 10(Suppl 33): S4162-S4164. DOI: 10.21037/jtd.2018.10.39. doi:10.21037/jtd.2018.10.39
[18]	Qi S, Mao Y, Jiang M. A phase Ⅰ study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer[J]. Cancer Chemother Pharmacol, 2019, 84(5): 1115-1123. DOI: 10.1007/s00280-019-03944-w. doi:10.1007/s00280-019-03944-w
[19]	吴小源, 邢文群, 李雪, 等. 尼妥珠单抗联合术前同期放化疗治疗局部进展期食管鳞癌初步临床研究[J]. 中华放射肿瘤学杂志, 2019, 28(3): 185-187. DOI: 10.3760/cma.j.issn.1004-4221.2019.03.005. doi:10.3760/cma.j.issn.1004-4221.2019.03.005
[20]	Chen Y, Wu X, Hao D, et al. Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma[J]. Oncotarget, 2019, 10(40): 4069-4078. DOI: 10.18632/oncotarget.23861. doi:10.18632/oncotarget.23861
[21]	康静静, 惠周光. 食管癌术后放疗研究现状[J]. 临床外科杂志, 2016, 24(7): 562-565. DOI: 10.3969/j.issn.1005-6483.2016.07.026. doi:10.3969/j.issn.1005-6483.2016.07.026
[22]	Liang H, Fan JH, Qiao YL. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China[J]. Cancer Biol Med, 2017, 14(1): 33-41. DOI: 10.20892/j.issn.2095-3941.2016.0093. doi:10.20892/j.issn.2095-3941.2016.0093pmid:28443201
[23]	Ramos-Suzarte M, Lorenzo-Luaces P, Lazo NG, et al. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy[J]. Cancer Biol Ther, 2012, 13(8): 600-605. DOI: 10.4161/cbt.19849. doi:10.4161/cbt.19849pmid:22555809
[24]	Saumell Y, Sanchez L, González S, et al. Overall survival of patients with locally advanced or metastatic esophageal squamous cell carcinoma treated with nimotuzumab in the real world[J]. Adv Ther, 2017, 34(12): 2638-2647. DOI: 10.1007/s12325-017-0631-7. doi:10.1007/s12325-017-0631-7
[25]	de Castro Junior G, Segalla JG, de Azevedo SJ, et al. A randomised phase Ⅱ study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: nice trial[J]. Eur J Cancer, 2018, 88: 21-30. DOI: 10.1016/j.ejca.2017.10.005. doi:10.1016/j.ejca.2017.10.005
[26]	刘慧娟, 车宇, 刘佳. 尼妥珠单抗联合同步放、化疗治疗中晚期食管癌的近期疗效观察[J]. 现代肿瘤医学, 2015, 23(18): 2587-2590. DOI: 10.3969/j.issn.1672-4992.2015.18.10. doi:10.3969/j.issn.1672-4992.2015.18.10
[27]	安志玲, 林宇. 调强放射治疗同步化疗联合或不联合尼妥珠单抗治疗局部晚期颈部食管鳞癌近期疗效的观察[J]. 内蒙古医科大学学报, 2022, 44(1): 23-25, 30. DOI: 10.16343/j.cnki.issn.2095-512x.20210825.001. doi:10.16343/j.cnki.issn.2095-512x.20210825.001
[28]	傅国林. 尼妥珠单抗在局部晚期食管癌同步放化疗中的疗效观察[J]. 中国基层医药, 2017, 24(22): 3457-3461. DOI: 10.3760/cma.j.issn.1008-6706.2017.22.025. doi:10.3760/cma.j.issn.1008-6706.2017.22.025
[29]	王旭, 张洁, 陈宏宏. 同步放化疗联合尼妥珠单抗治疗食管癌的疗效及预后因素分析[J]. 癌症进展, 2020, 18(17): 1782-1785, 1805. DOI: 10.11877/j.issn.1672-1535.2020.18.17.16. doi:10.11877/j.issn.1672-1535.2020.18.17.16
[30]	Jing W, Yan W, Liu Y, et al. Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma[J]. Cancer Biol Ther, 2019, 20(8): 1121-1126. DOI: 10.1080/15384047.2019.1598760. doi:10.1080/15384047.2019.1598760
[31]	师颖瑞, 王晖, 杨敬儒, 等. 食管癌后程加速超分割调强适形放疗及联用尼妥珠单抗的研究[J]. 肿瘤研究与临床, 2014, 26(8): 514-517, 522. DOI: 10.3760/cma.j.issn.1006-9801.2014.08.003. doi:10.3760/cma.j.issn.1006-9801.2014.08.003
[32]	Guo JH, Chen MQ, Chen C, et al. Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma[J]. Mol Clin Oncol, 2015, 3(5): 1135-1138. DOI: 10.3892/mco.2015.606. doi:10.3892/mco.2015.606
[33]	李路路, 陈剑, 张鼎儒, 等. 尼妥珠单抗联合IMRT治疗老年局部晚期食管癌患者的疗效观察[J]. 现代肿瘤医学, 2020, 28(8): 1298-1300. DOI: 10.3969/j.issn.1672-4992.2020.08.013. doi:10.3969/j.issn.1672-4992.2020.08.013
[34]	Yang X, Zhai Y, Bi N, et al. Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: a phase Ⅱ clinical trial[J]. Chin J Cancer Res, 2021, 33(1): 53-60. DOI: 10.21147/j.issn.1000-9604.2021.01.06. doi:10.21147/j.issn.1000-9604.2021.01.06
[35]	童华杰, 张远强, 杨纯平, 等. 不同铂类化疗方案对中晚期食管癌调强适形放疗患者的预后影响[J]. 中国临床药理学杂志, 2019, 35(1): 20-23. DOI: 10.13699/j.cnki.1001-6821.2019.01.006. doi:10.13699/j.cnki.1001-6821.2019.01.006
[36]	Lai X, Gu Q, Zheng X, et al. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: a retrospective study[J]. J Cancer Res Ther, 2016, 12(Supplement): 89-95. DOI: 10.4103/0973-1482.191612. doi:10.4103/0973-1482.191612
[37]	Lu M, Wang X, Shen L, et al. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: a single centre prospective phase Ⅱ trial[J]. Cancer Sci, 2016, 107(4): 486-490. DOI: 10.1111/cas.12894. doi:10.1111/cas.12894
[38]	Zhang X, Jia J, Lu M, et al. Nimotuzumab plus paclitaxel and cisplatin as a 1^st-line treatment for esophageal cancer: long term follow-up of a phase Ⅱstudy[J]. J Cancer, 2019, 10(6): 1409-1416. DOI: 10.7150/jca.28659. doi:10.7150/jca.28659
[39]	杜彬, 吴日平, 王尧, 等. 尼妥珠单抗联合紫杉醇及顺铂治疗晚期食管癌疗效观察[J]. 海峡药学, 2018, 30(12): 123-125. DOI: 10.3969/j.issn.1006-3765.2018.12.056. doi:10.3969/j.issn.1006-3765.2018.12.056
[40]	Peng C, Cohen DJ. Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma[J]. Expert Opin Pharmacother, 2021, 22(1): 93-107. DOI: 10.1080/14656566.2020.1813278. doi:10.1080/14656566.2020.1813278